Evidence map›Paper›PMID 40573898›Full record

ArticleVaccines2025

FcRn-Driven Nanoengineered Mucosal Vaccine with Multi-Epitope Fusion Induces Robust Dual Immunity and Long-Term Protection Against

Tingting Tian, Yuejie Zhu, Kaiyu Shang, Huidong Shi, Ruixue Xu, Mingzhe Li, Fuling Pu, Junyu Kuang, Jianbing Ding, Fengbo Zhang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Vaccines, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Mucosal immunity and vaccine development.Signal transduction and targeted therapy · 2026
    Pooled it
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Tingting TianState Key Laboratory of Pathogenesis, Prevention and Treatment of High-Incidence Diseases in Central Asia, The First Affiliated Hospital of Xinjiang Medical University, Graduate School, Clinical Laboratory Diagnostics, Urumqi 830000, China.
Yuejie ZhuReproductive Fertility Assistance Center, The First Affiliated Hospital of Xinjiang Medical University, Urumqi 830000, China.
Kaiyu ShangState Key Laboratory of Pathogenesis, Prevention and Treatment of High-Incidence Diseases in Central Asia, The First Affiliated Hospital of Xinjiang Medical University, Graduate School, Clinical Laboratory Diagnostics, Urumqi 830000, China.
Huidong ShiState Key Laboratory of Pathogenesis, Prevention and Treatment of High-Incidence Diseases in Central Asia, The First Affiliated Hospital of Xinjiang Medical University, Graduate School, Clinical Laboratory Diagnostics, Urumqi 830000, China.
Ruixue XuDepartment of Medical Laboratory Technology, School of Medicine, Xinjiang Medical University, Urumqi 830000, China.
Mingzhe LiDepartment of Medical Laboratory Technology, School of Medicine, Xinjiang Medical University, Urumqi 830000, China.
Fuling PuDepartment of Medical Laboratory Technology, School of Medicine, Xinjiang Medical University, Urumqi 830000, China.
Junyu KuangDepartment of Medical Laboratory Technology, School of Medicine, Xinjiang Medical University, Urumqi 830000, China.
Jianbing DingState Key Laboratory of Pathogenesis, Prevention and Treatment of High-Incidence Diseases in Central Asia, The First Affiliated Hospital of Xinjiang Medical University, Graduate School, Clinical Laboratory Diagnostics, Urumqi 830000, China.
Fengbo ZhangState Key Laboratory of Pathogenesis, Prevention and Treatment of High-Incidence Diseases in Central Asia, The First Affiliated Hospital of Xinjiang Medical University, Graduate School, Clinical Laboratory Diagnostics, Urumqi 830000, China.ORCID 0000-0001-5795-8672

Funding

the Central Government Guides Local Science and Technology Development Fund Project ZYYD2025ZY19the Natural Science Foundation of China No. 82360394，82460399the Outstanding Youth Project of the Autonomous Region No.2023D01E12the Youth Science and Technology Top Talent Project No.2022TSYCCX0112
6 · The paper itself

Abstract

backgroundBrucellosis poses a significant public health challenge, necessitating effective vaccine development. Current vaccines have limitations such as safety concerns and inadequate mucosal immunity. This study aims to develop an FcRn-targeted mucosal

methodsThe study developed a recombinant antigen (h-tFc-MEV) through computational analyses to validate antigenicity, structural stability, solubility, and allergenic potential. Molecular simulations confirmed FcRn binding. The vaccine was delivered orally via chitosan nanoparticles in murine models. Immunization was compared to MEV-only immunization. Post-challenge assessments were conducted to evaluate protection against

resultsComputational analyses showed that the antigen had favorable properties without allergenic potential. Molecular simulations demonstrated robust FcRn binding. In murine models, oral delivery elicited enhanced systemic immunity with elevated serum IgG titers and amplified CD4+/CD8+ T-cell ratios compared to MEV-only immunization. Mucosal immunity was evidenced by significant IgA upregulation across multiple tracts. Long-term immune memory persisted for six months. Post-challenge assessments revealed markedly reduced

conclusionsThe FcRn-targeted strategy establishes concurrent mucosal and systemic protective immunity against

Indexed as

FcRn: neonatal Fc receptorMEV: multi-epitope vaccinemucosal vaccine

Identifiers

PMID40573898
PMCPMC12197398

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.